论文部分内容阅读
目的:观察银杏达莫注射液联合厄贝沙坦(ARB)治疗早期糖尿病肾病(DN)临床疗效。方法:将80例糖尿病患者随机分为治疗组和对照组各40例,实验组仅给予厄贝沙坦治疗,对照组给予厄贝沙坦联合银杏达莫注射液治疗。2组疗程均为6周。观察2组尿素氮(BUN)、血肌酐清除率(CCr)、三酰甘油(TG)、空腹血糖(FBG)、尿微量蛋白排泄率(UAER)指标变化。结果:治疗后2组BUN、CCr、FBG、UAER水平均较治疗前显著降低(P<0.05),实验组治疗后TG水平显著降低(P<0.05),对照组治疗前后TG水平无差异(P>0.05);实验组治疗后BUN、CCr、TG、UAER水平均显著低于对照组,差异均有统计学意义(P<0.05)。结论:银杏达莫注射液联合厄贝沙坦治疗早期糖尿病肾病(DN),在降低空腹血糖、BUN、CCr的变化方面明显优于单用厄贝沙坦,能有效地保护肾功能,并且能延缓糖尿病肾病的发展。
Objective: To observe the clinical efficacy of gingko Damo injection combined with irbesartan (ARB) in the treatment of early diabetic nephropathy (DN). Methods: 80 cases of diabetic patients were randomly divided into treatment group and control group of 40 cases, the experimental group was given irbesartan only, the control group was given irbesartan combined with gingko Damo injection. The two courses of treatment were 6 weeks. The changes of BUN, CCr, TG, FBG and UAER in the two groups were observed. Results: The levels of BUN, CCr, FBG and UAER in the two groups after treatment were significantly lower than those before treatment (P <0.05), while TG levels in the experimental group were significantly decreased after treatment (P <0.05) > 0.05). The levels of BUN, CCr, TG and UAER in the experimental group were significantly lower than those in the control group (P <0.05). CONCLUSION: Ginkgo biloba injection combined with irbesartan in the treatment of early diabetic nephropathy (DN) is superior to irbesartan alone in reducing the changes of fasting blood glucose, BUN and CCr, and can effectively protect renal function Delays the development of diabetic nephropathy.